News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Optibrium Announces A New Release Of StarDrop Introducing MPO Explorer



1/14/2014 9:41:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, UK, 14 January, 2014 – Optibrium™, a developer of software for drug discovery, today announced the release of a new version of its StarDrop™ software platform. The latest release introduces MPO Explorer™, which provides innovative new methods to guide ‘strategic’ decisions in research programmes, by helping to identify the key properties and selection criteria with which to select compounds with a high chance of success. The new module, alongside data visualisation enhancements, further extends StarDrop’s capabilities to reduce the time and cost to deliver high quality drug candidates.

MPO Explorer introduces unique (patent pending) methods that guide the development and validation of multi-parameter scoring profiles, tailored to a discovery project’s specific objectives. The resulting scoring profiles can be applied with StarDrop’s Probabilistic Scoring approach for multi-parameter optimisation (MPO), to effectively target novel compounds with a high chance of success. The most important property criteria are also highlighted, focussing experimental resources to generate the key data with which to identify successful compounds. To promote objective decision making, the new module also tests if a specific property criteria in a scoring profile may be artificially distorting the selection of compounds to pursue. If a small change in a criterion would lead to a different decision, this can highlight new avenues for exploration and avoid missed opportunities.

These new capabilities are supported by further enhancements to the core StarDrop application, including new data visualisation features such as 3D scatter and chemical space plots. In addition, StarDrop’s R-group analysis tool has been extended to perform matched pair analysis, providing insight into the key substitutions in a chemical series that have a significant impact on a compound’s properties.

Dr Matthew Segall, Optibrium’s CEO, commented: “StarDrop now offers our users a comprehensive desktop environment to guide strategic decisions in their drug discovery projects, optimise the use of resources and intuitively target compounds with an improved chance of success. The latest release delivers new technologies that represent the culmination of years of leading edge research and further our goals to improve the efficiency and productivity of our customers’ discovery projects.”

For further information on Optibrium and StarDrop 5.5, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

For high resolution image please email sarah.jeffery@zymecommunications.com
Media contact
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919

Optibrium
Nick Foster
Director, Business Development
E-mail: nick@optibrium.com
Phone: +44 (0)1223 815900

About Optibrium Ltd.

Optibrium provides drug discovery software solutions that bring confidence to the selection and design of high quality candidate drugs. The Company’s flagship platform, StarDrop, creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective drug candidates with a high probability of success downstream.

Founded in 2009, Optibrium continues to develop StarDrop and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma companies, biotech and academic groups.

Visit the online community at www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES